Lahjavida
Lahjavida is a pioneering cancer research company focused on developing innovative dye drug conjugates for targeted cancer therapy. Their mission is to improve and extend the gift of life for cancer patients by creating safer, more effective treatments that precisely target tumors while protecting healthy tissues. With over 25 years of expertise in tumor-targeting dye technology and a strategic approach combining dyes, linkers, and chemotherapy drugs, Lahjavida aims to revolutionize cancer care across multiple cancer types, including metastatic tumors.
Industries
Nr. of Employees
small (1-50)
Lahjavida
1096 Elkton Dr., Suite 600, Colorado Springs, CO 80907
Patents
Products
Dye–Drug Conjugate (DDC) platform
A small-molecule platform that links a tumor-targeting near-infrared dye to standard chemotherapy drugs via a cleavable linker; designed to remain inactive in circulation, preferentially accumulate in tumors, and release active drug intracellularly.
Dye–Drug Conjugate (DDC) platform
A small-molecule platform that links a tumor-targeting near-infrared dye to standard chemotherapy drugs via a cleavable linker; designed to remain inactive in circulation, preferentially accumulate in tumors, and release active drug intracellularly.
Services
Design and execution of in vitro (2D), organoid, and in vivo studies to assess tumor targeting, penetration, efficacy, and toxicity of conjugates.
Synthesis and small-batch manufacture of dye–drug conjugates and dye–gold conjugates for preclinical experimentation.
Near-infrared imaging to track systemic distribution, tumor accumulation, retention and clearance of conjugates in preclinical models.
Research partnerships and advisory engagement with university laboratories and clinical researchers to independently test and validate conjugate performance.
Design and execution of in vitro (2D), organoid, and in vivo studies to assess tumor targeting, penetration, efficacy, and toxicity of conjugates.
Synthesis and small-batch manufacture of dye–drug conjugates and dye–gold conjugates for preclinical experimentation.
Near-infrared imaging to track systemic distribution, tumor accumulation, retention and clearance of conjugates in preclinical models.
Research partnerships and advisory engagement with university laboratories and clinical researchers to independently test and validate conjugate performance.
Expertise Areas
- Targeted drug delivery
- Tumor-targeting dye development
- Nanoparticle-mediated hyperthermia
- Preclinical research (organoids and animal models)
Key Technologies
- Near-infrared (NIR) fluorescent dyes
- Cleavable linker chemistry
- Gold nanoparticle conjugation (~20 nm)
- Radiowave-induced nanoparticle heating
News & Updates
Lahjavida has made significant progress in cancer treatment by developing dye drug conjugates that target over 30 cancer types, delivering chemotherapy directly to tumors with high precision and minimal toxicity. The technology involves tumor-targeting dyes, specialized linkers, and standard chemotherapy drugs, which activate inside cancer cells to destroy them while sparing healthy tissue.
Lahjavida has made significant progress in cancer treatment by developing dye drug conjugates that target over 30 cancer types, delivering chemotherapy directly to tumors with high precision and minimal toxicity. The technology involves tumor-targeting dyes, specialized linkers, and standard chemotherapy drugs, which activate inside cancer cells to destroy them while sparing healthy tissue.